| Literature DB >> 33037066 |
Alina Baum1, Dharani Ajithdoss1, Richard Copin1, Anbo Zhou1, Kathryn Lanza1, Nicole Negron1, Min Ni1, Yi Wei1, Kusha Mohammadi1, Bret Musser1, Gurinder S Atwal1, Adelekan Oyejide1, Yenny Goez-Gazi2, John Dutton2, Elizabeth Clemmons2, Hilary M Staples2, Carmen Bartley2, Benjamin Klaffke2, Kendra Alfson2, Michal Gazi2, Olga Gonzalez2, Edward Dick2, Ricardo Carrion2, Laurent Pessaint3, Maciel Porto3, Anthony Cook3, Renita Brown3, Vaneesha Ali3, Jack Greenhouse3, Tammy Taylor3, Hanne Andersen3, Mark G Lewis3, Neil Stahl1, Andrew J Murphy1, George D Yancopoulos1, Christos A Kyratsous4.
Abstract
An urgent global quest for effective therapies to prevent and treat coronavirus disease 2019 (COVID-19) is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987 and REGN10933) that targets nonoverlapping epitopes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques, which may model mild disease, and golden hamsters, which may model more severe disease. We demonstrate that REGN-COV-2 can greatly reduce virus load in the lower and upper airways and decrease virus-induced pathological sequelae when administered prophylactically or therapeutically in rhesus macaques. Similarly, administration in hamsters limits weight loss and decreases lung titers and evidence of pneumonia in the lungs. Our results provide evidence of the therapeutic potential of this antibody cocktail.Entities:
Mesh：
Substances：
Year: 2020 PMID： 33037066 PMCID： PMC7857396 DOI： 10.1126/science.abe2402
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728